Ariana Pelosci

The anti-PD-1 antibody spartalizumab demonstrated promising responses in patients with recurrent/metastatic nasopharyngeal cancer.

Patients have higher odds of experiencing rapid relapse in triple-negative breast cancer if they have Medicaid or no insurance, are single, are Black, and have not undergone surgery.

Patients taking teclistamab for relapsed or refractory multiple myeloma saw durable response, and a well-tolerated toxicity profile.

The recommended phase 2 dose for lenvatinib was 14 mg/m2 in relapsed/refractory osteosarcoma.

A large meta-analysis showed a one-third reduction in recurrence or death in patients with HER2-positive early breast cancer with 1 year of trastuzumab added to chemotherapy, confirming the benefit of this therapy across baseline characteristics.

A 3-arm randomized study indicated that domvanalimab-based combinations yielded a promising overall response rate for patients with metastatic non–small cell lung cancer with a PD-L1 status of 50% or more.

A number of prognostic and treatment related factors have been found to impact health-related quality of life among survivors of breast cancer.

Patients with cancer and those without cancer had similar serologic results 6-months after receiving their second BNT162b2 vaccine.

Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.

High intensity interval training yielded decreased prostate-specific antigen levels and velocity, as well as lowering prostate cell growth in men with localized prostate cancer.

Patients with advanced nasopharyngeal carcinoma and who were treated with gemcitabine plus cisplatin experienced a longer overall survival and improved progression-free survival vs fluorouracil plus cisplatin.

Latina breast cancer survivors are less likely to seek counseling due to concerns that the counselor will not understand their values or have linguistic challenges.

Low study quality was determined in an analysis of real-world studies across multiple drug indications in cancer.

Survivorship incorporated into primary cancer care may be more cost effective and lead to better clinical and patient-reported outcomes in patients with breast cancer and other malignancies.

Patients with non–small cell lung cancer and small-cell lung cancer with bone metastases may benefit from extended dosing with zoledronic acid.

Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.

Patients with high-risk early breast cancer who received zoledronate for over 2 years did not experience an improvement in prognosis.

The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.

Geriatric patients with prostate cancer did not experience a decline in cognative function regardless of treatment.

Patients with myelodysplastic syndromes showed favorable event-free survival with allogeneic stem cell transplant compared with those being treated with continuous 5-azacytidine.

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.

Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.

Young-adult cancer survivors who met criteria for being prefrail and frail were more likely to experience a cognitive decline compared with those considered to be nonfrail.

Hippocampal avoidance–prophylactic cranial irradiation was associated with better cognitive function preservation versus standard prophylactic cranial irradiation for small cell lung cancer.

PET-negative patients who are treated with radiotherapy had a slightly increased absolute cardiovascular disease risk, although magnitude of these effects varied widely.

Analysis of women who have survived breast cancer reveal impacts on sexual life.

The topline results from the DeCidE1 trial showing promising results for patients with ovarian cancer treated with maverpopemiut-S.

Patients with solid tumors experienced significant immunogenicity within 2 weeks of receiving a second dose of the BNT162b2 COVID-19 vaccine.

The phase ORIENT-16 trial indicated that the addition of sintilimab to chemotherapy significantly improved of overall survival compared with placebo.